Introduction
============

In 1970, the Rockefeller Foundation introduced the term "the Great Neglected Diseases," corresponding to several illnesses caused by infectious microorganisms and parasites (viruses, bacteria, fungi, protozoa, and helminthes), endemic in poor populations of Asia, Africa, and America. Neglected diseases received this name due to the lack of interest by health science researchers and pharmaceutical companies on developing and commercializing products for their treatment or cure. Consequently, studies on this field are poorly invested ([@B88]).

However, during the last 20 years, the pattern of neglected diseases worldwide has changed, as mortality rates are decreasing, while morbidity still grows on the population. All neglected diseases are closely related to poverty, lack of hygiene, food and quality of life. Therefore, it is difficult to include long-time treatment programs, as most of the patients have no financial conditions to pay for the drugs ([@B75]; [@B13]).

Chagas diseases, Leishmaniasis, and Malaria are some of these neglected diseases. Chagas disease, first reported in America during 1909, was classified as an enzootic illness affecting mostly the poor population of Latin America. Nevertheless, nowadays, it became a worldwide concern, as it spread through many countries in Africa, Europe, and Asia ([@B27]; [@B105], [@B106]). Migration processes of contaminated people to non-endemic regions and environmental changes in forestry areas, favoring trypanosome parasites to adapt into domestic environment, increased the identification of Chagas disease cases in North America, Western Pacific region and at least 16 countries of Europe. Therefore, new forms of parasite transmission were described, including blood transfusion, organ transplantation, and vertical transmission from mother to child ([@B27]; [@B105]). The constant migration of people from different countries during the last two decades enlarged epidemiological and social matters, leading to an evaluation of economic and political aspects for the prevention, treatment, and eradication of this disease ([@B106]).

Leishmaniasis is another neglected disease with high concern to many countries worldwide. In February, the [@B107] estimated 1.3 million new cases of Leishmaniasis (visceral and cutaneous) and 20,000--30,000 deaths annually. The cutaneous form of Leishmaniasis occurs in different populations of the world, although higher rates are observed in South American and African countries. On the other hand, 90% of all cases of visceral Leishmaniasis is concentrated in Bangladesh, Brazil, Ethiopia, India, Sudan, and South Sudan ([@B2]). In Brazil, Leishmaniasis is showing an expansion, generally associated with environmental modification caused by man, population displacements arising from endemic areas and insufficient infrastructure in water and sewer systems ([@B75]; [@B13]).

Additionally, Malaria is one of the most important parasitic infectious disease of the world. It occurs in tropical and subtropical areas of 106 countries worldwide. Only in 2012, 627,000 1000 people in the Saharan Africa died of Malaria ([@B21]). Although an estimative from the World Malaria Report consider a significant decrease in the number of countries exposed to Malaria (from 140 to 106), every year, 100s of millions of new episodes are registered in different regions of the world ([@B80]; [@B108]).

Most of neglected diseases have low financial support, both from Private and Governmental funds. However, great amount of international funding is given to control new cases of Malaria in endemic countries, as well as applied on preventive Programs for poor populations. The amount invested on the control of Malaria worldwide raised from US\$ 960 million in 2005 to US\$ 2.5 billion in 2014 ([@B108]). The number increased 8% between 2013 and 2014, but the financial support invested on the prevention and treatment of Malaria are still not sufficient to contain the arrival of new cases.

Hence, part of the financial investments applied on Malaria, Leishmaniasis, and Chagas' disease is spent on research for the discovery of novel molecules that can be used as new pharmaceutical products for the treatment of these illnesses. Recently, studies demonstrated that the use of peptides isolated from host mosquitoes and other invertebrates, called anti-parasitic peptides (APPs), are the key to inhibit or even kill protozoa cells infecting the human body ([@B63]; [@B71]; [@B95]; [@B33]; [@B38]; [@B83]; [@B68]).

Therefore, this report describes the first studies related to the activity of different peptides from insect hosts APPs against three parasite species: *Trypanosoma* sp., *Leishmania* sp., and *Plasmodium* sp. The results reported here show the great potential of using insect host proteins and peptides to treat Chagas disease, Leishmaniasis, and Malaria in human patients.

New Strategies for the Treatment of Chagas Disease
==================================================

Chagas disease is a human trypanosomiasis endemic in Latin America countries, caused by the species *Trypanosoma cruzi*. The name was given by the scientist Carlos Chagas, in honor of the research developed by Oswaldo Cruz, during the beginning of the 20th century. The transmission occurs when a person is bitten by a triatomine insect containing *T. cruzi* parasites ([@B30]). Common triatomines of Chagas disease vectors belong to *Triatoma, Rhodnius*, and *Panstrongylus generi.* In Central and South America, the most common triatomine is *T. prolixus* ([@B33]).

Chagas' disease can be classified into three different stages: acute, asymptomatic, and chronic. The acute stage consists of fever, facial edema, generalized lymphadenopathy, and hepatosplenomegaly. Usually, 5% of contaminated children die during this stage, but the illness can spontaneously undertake itself in 4--6 weeks, becoming asymptomatic. During this stage, also called indeterminate, the parasite passes to its second phase, which can last from 10 years to a lifetime. The last and most concerning stage is the chronic phase, once the disease can compromise the heart, leading to death by cardiac arrhythmia or congestive heart failure ([@B103]; [@B30]). Therefore, Chagas disease has become one of the main causes of heart problems in Latin America countries, as well as gastrointestinal mega-syndromes in some patients ([@B23]; [@B77]).

It is estimated that 11 million people in American countries are infected with *T. cruzi*, and 10--30% of them will develop the chronic stage of Chagas disease ([@B7]). There is no cure for Chagas disease and the available treatments correspond to the use of benznidazole or nifurtimox. Both are effective only in 50% of the cases, and for patients in the acute or early indeterminate stages. There is still no treatment, nor even a cure, for the late indeterminate and chronic stages of Chagas disease ([@B50]; [@B103]; [@B37]).

Until now, there are also no vaccines developed to prevent infection by *T. cruzi*, neither effective vector eradication Programs to control parasite dissemination ([@B51]). Thus, there is a strong need for the development of adequate therapeutic strategies to treat Chagas disease. Preliminary work described the use of peptides capable of lysing different cell types ([@B49]). Therefore, the utilization of proteins and peptides from different sources became a strategic alternative for the control of parasites.

Another interesting feature is the inability of parasites to damage the cells of their insect hosts. Although, the infection with the parasite can cause several damages in human organs, it is harmless to triatomine insects ([@B84]). In this way, investigating proteins and peptides from parasite's insect hosts is a prospering alternative for the development of new tools against Chagas disease.

Anti-trypanosomal Peptides
--------------------------

There are still, in literature, very few studies on the prospection and evaluation of the anti-trypanosomal effect of proteins and peptides from insect sources, especially for species causing Chagas disease. Among all classes of proteic molecules, only three have been studied for this purpose: apidaecins, cecropins, and melittins (**Table [1](#T1){ref-type="table"}**).

###### 

Insect peptides with anti-parasitic activity.

  Anti-parasitic activity   Peptide         Insect species              Targeted parasite(s)          Half maximal inhibitory concentration (IC~50~)   Mortality rate           Reference
  ------------------------- --------------- --------------------------- ----------------------------- ------------------------------------------------ ------------------------ -----------
  Anti-tripanosomal         Cecropin        *Hyalophora cecropia*       *Trypanosoma cruzi*           0.8 μM                                           NI                       [@B33]
                            Melittin        *Apis melífera* venom       *T. cruzi*                    0.8 μM                                           NI                       [@B33]
                            Meucine-24      *A. melífera* venom         *T. cruzi*                    10--20 μM                                        NI                       [@B38]
  Anti-malarial             Cecropin B      *H. cecropia*               *Plasmodium* sp.              0.5 μg/μl (128 μM)                                                        [@B40]
                            Cecropin A      *H. cecropia*               *P. falciparum*               \>100 μM                                         NI                       [@B12]
                            Drosomycin 1    *Drosophila melanogaster*   *P. berghei*                  NI                                               76% mortality at 20 μM   [@B95]
                            Drosomycin 2    *D. melanogaster*           *P. berghei*                  NI                                               29% mortality at 20 μM   [@B95]
                            Gambicin        *Anopheles* sp.             *P. berghei*                  10 μM                                            NI                       [@B101]
                            Gomesin         *A. gomesi*                 *P. falciparum, P. berghei*   75.8--86.6 μM                                    NI                       [@B71]
                            Meucine-25      *Mesobuthus eupeus*         *P. berghei*                  10--20 μM                                        NI                       [@B38]
                            Scorpine        *Pandinus imperator*        *P. berghei*                  NI                                               98% mortality at 15 μM   [@B16]
                                                                        *P. falciparum*               NI                                               100% mortality at 5 μM   [@B16]
  Anti-leishmanial          Decoralin       *Oreumenes decoratus*       *L. major*                    72 μM                                            NI                       [@B56]
                            Decoralin-NH2   Derived from Decoralin      *L. major*                    11 μM                                            NI                       [@B56]
                            Eumenitin       *Eumenesru rubronotatus*    *Leishmania* sp.              35 μM                                            NI                       [@B83]
                            Spinigerin      *P. messpiniger*            *L. donovani*                 150 μM                                           NI                       [@B58]
                            Tachyplesin     *Tachypleus tridentatus*    *L. braziliensis*             12.5 μM                                          NI                       [@B64]

NI, not indicated by the authors.

Apidaecins correspond to a group of small prolin-rich peptides, ranging from 18 to 20 amino acid residues, previously isolated from the honeybees *Apis melifera* ([@B19]; [@B63]). They have been widely studied as potential molecules for therapeutic use due to their anti-bacterial activity and harmless impact against human and animal cells ([@B20]; [@B63]). Recent studies showed that this class of peptides can also present anti-trypanocidal activity at an absolute lethal concentration (LC~100~) of 199 μM ([@B33]). Moreover, when used in pairwise treatments, together with magainin II (from the *Xenopus laevis*), cecropin (from the silk worm) and melittin (also from honeybee), the anti-trypanocidal activity increased 10 folds, showing additive effects at a half maximal inhibitory concentration (IC~50~) of 0.70 μM ([@B33]).

Cecropins include a class of small and basic peptides of about 31--37 amino acid residues. They were first isolated from the silk moth *Hyalophora cecropia*, and have been described as an important molecule in the cell-free immunity of insects, with activity against bacteria and fungi growth ([@B10]; [@B11]). Earlier studies demonstrated the performance of synthetic cecropins against *T. cruzi.* The synthetic peptides, called SB-37 and Shiva-1, with punctual mutations in their amino acid sequence, were able to kill trypomastigote forms of the parasite after 1-h exposure, in a dose-responsive manner ([@B44]). Interestingly, Shiva-1 peptide was 10 times more effective against Trypomastigotes than SB-37, in terms of parasite damage and lysis.

Another report showed that a Cecropin A displayed trypanostatic effects against Chagas diseases parasite, inhibiting its growth at a LC~100~ of 80 μM, although it was not able to kill *T. Cruzi* cells ([@B33]). However, when coupled with other peptides, such as magainin, an antagonistic effect was observed, at a concentration of 0.1 and 1.0 μM for cecropin and magainin, respectively ([@B33]).

Furthermore, melittin is a small 26-amino acid peptide isolated from honeybee venom with anti-microbial activity against yeasts and bacteria ([@B66]; [@B54]; [@B60]). It also has showed ability to inhibit protein kinase C, protein kinase II, and myosin kinase ([@B110]). Previous reports described the potential use of melittin on the treatment of epilepsy, HIV infection, and cancer ([@B65]; [@B42]; [@B99]). Further studies demonstrated that melittin present inhibitory activity against trypomastigotes (LD~100~ = 30 μM). Also, when coupled with apidaecin, the parasite inhibitory activity was increased. Nevertheless, when melittin was coupled with cecropin, it showed an antagonistic effect, contrary to the additive effect demonstrated with apidaecin ([@B33]).

*Leishmania* sp.: A Mammalian Parasite to be Defeated
=====================================================

*Leishmania* is a genus of protozoa transmitted between mammals by blood-sucking sandflies. Mammal species, including dogs, mice and humans, are natural hosts for *Leishmania* and in some parts of the world, like India, humans are the main hosts ([@B47]). The parasite's live cycle encompasses a differentiation of procyclic promastigote form into infective metacyclic promastigote. This stage occurs inside sandflies, where the parasite will be ready for transmission at the stomodea valve's insect. During blood-sucking, contaminated sandflies can inject metacyclic promastigotes into mammal tissues together with some parasite immunomodulatory elements. After phagocytized by host cells, parasites will accommodate inside human body. Then metacyclic promastigotes can become flagellate amastigote and replicates into host cells driving them to rupture, spreading amastigotes into host tissues and allowing infection of others phagocytes. The cycle is completed when infected phagocytes are sucked by another sand-fly and are converted in promastigotes into sand-fly's midgut, re-starting a new cycle ([@B47]).

There are more than 20 species of *Leishmania* related to several subtypes of chronic skin and viscera infections, classified as mucocutaneous disease, visceral disease, Leishmaniasis recidivism, and post-kala-azar dermal Leishmaniasis ([@B69]). Around 1.3 million cases of Leishmaniasis are reported annually worldwide and there is an estimative that 350 million people in 88 countries are living at risk of developing Leishmaniasis ([@B48]; [@B107]).

There is a huge number of drug treatment available to each form of Leishmaniasis. Pentavalent antimony is the agent of choice for the majority forms of such disease ([@B5]). Amphotericin B, Paromomycin, Pentamidine also have been used worldwide ([@B43]; [@B25]; [@B90]). However, these drugs are often harmful to the patient, the treatments need constant follow up and patients may not be 100% recovered ([@B69]). Therefore, new strategies to treat Leishmaniasis is a clear need for millions of patients around the world.

Anti-leishmanial Peptides
-------------------------

Some APPs were reported as acting against *Leishmania* species and have been considered a low harmful alternative, despite of current drugs used to control *Leishmania* infections ([@B22]). [@B68] listed some leishmanicidal peptides, such as Temporins, Bombins, Magainins, and Cathelicidins (from amphibians and mammalians), and discussed their mechanism of action. Arthropods Leishmanicidal peptides are described in **Table [1](#T1){ref-type="table"}**.

Hence, among the APPs from insect sources, there is Spinigerin. It is a cysteine-free peptide constitutively expressed by termite *Pseudacanthotermes spiniger.* Its minimal inhibitory concentration (MIC) in bioassays against filamentous fungi, yeast, gram-negative bacteria is \<5 μM ([@B58]). When assayed against *Leishmania donovani*, spinigerin was able to cause apoptosis-like cell death (IC~50~, 150 μM). [@B58] suggested that such peptide could cause such effects by inhibiting some Leshimanial trypanothione reductase, thus, arresting detoxification processes against reactive oxygen species (ROS) produced by the host cells.

Eumenitin is a class of small cationic peptides (15 amino acids) from the venom of the solitary eumenine *Eumenes rubronotatus*, which was isolated and characterized by [@B55]. Its activity against Gram-positive and Gram-negative bacteria, as well as its capacity to stimulate degranulation of mast cells are known since its discovery. However, eumenitin's leishimanicidal activity was reported only in [@B83], when the peptide was assayed against *Leishmania major*, displaying anti-parasitic effects at IC~50~ of 35 μM.

Decoralin belongs to a class of small and linear cationic α-helical peptides not stabilized by disulfide bonds. It was isolated for the first time in [@B56] from the venom of the solitary eumenine wasp *Oreumenes decoratus*. Such class of peptides is known to adopt an amphipathic α-helical conformation, which was reported as essential for its biological activity ([@B79]). Hence, decoralin showed activity against *L. major* at micromolar concentrations (IC~50~ ~=~ 72 μM). But when the C-terminal of the peptide was amidated, the anti-parasitic activity demonstrated a IC~50~ sixfold lower, around 11 μM ([@B56]). Such enhance in its activity is speculated to be due a stabilization of α-helical conformation caused by C-terminal amidation, as well as an extra electrical charge provided by amidation ([@B86]).

Tachyplesin is a class of anti-microbial and APPs from horseshoe-crab (*Tachypleus tridentatus*), described for the first time in [@B72]. This peptide is 17 amino acids long and have a beta conformation, been active against Gram-positive and negative bacteria, as well as against virus and cancer cells ([@B87]). Bioassays using *Leishmania braziliensis* demonstrated that tachyplesin could also inhibit this parasite's growth at micromolar levels (12.5 μM; [@B64]).

Therefore, anti-leishmanicidal peptides from insect sources encompass a safe alternative to control *Leishmania* infection, once they are highly effective, but not as harmful as the current used drugs. The application of biotechnological tools for the large-scale production of such peptides are essential to aim this goal.

Malaria: New Approaches for the Control of *Plasmodium* Species
===============================================================

Malaria remains one of the most prevalent and debilitating parasitic infection across Africa, Asia, and America continents. According to the World Health Organization (WHO), approximately 207 million people were diagnosed with Malaria and 627,000 died worldwide from it during 2012 ([@B82]). Four species are the main cause of Malaria: *Plasmodium falciparum, P. vivax, P. malariae*, and *P. ovale*, transmitted by over 70 species of *Anopheles*' mosquitoes. Among the parasites, *P. falciparum* is the most severe and responsible for 90% of all malaria deaths ([@B39]).

*Plasmodium*'s life cycle is complex, involving multiple developing stages and locations, both in mosquitos and humans. Although its complex infectious cycle offers multiple sites for the development of specific drugs, finding a universal drug against malaria has been a challenging task. The major problem with the currently available anti-malarial drugs is the consistent resistance developed by some parasites, well-reported in literature ([@B9]; [@B102]; [@B17]; [@B96]). Recently, the emerging resistance toward the drug artemisinin decreased even more the chances for a cure of Malaria, once that it used as first-line treatment for uncomplicated cases caused by *P. falciparum*, in most endemic countries ([@B8]).

Therefore, the demand for novel therapeutic agents against Malaria is urgent, especially using new targets. Nowadays, the new generation of strategies involves the blockage of malaria transmission by employing genetically modified vectors, mosquito pathogens or symbionts that express anti-parasite molecules ([@B18]).

Additionally, APPs from the innate immune system of insect vectors have been used as sources to control sporogonic stages of the malaria parasites. There are three sources of APPs that are active against sporogonic forms of parasites: (1) Endogenous -- peptides that form part of the natural mosquito immune repertoire; (2) Exogenous -- peptides isolated from other species; and (3) Synthetic -- rational design of novel compounds ([@B17]).

Anti-malarial Peptides
----------------------

As there is a bigger number of studies on Malaria, there are also more peptides presenting activity against *Plasmodium* species isolated from different arthropods (**Table [1](#T1){ref-type="table"}**), including its insect host, *Anopheles* sp. ([@B40]; [@B101]; [@B52]; [@B6]).

Thus, during *Anopheles*'s *life* cycle, malaria mosquito vector (female anopheline) do not develop symptoms related to any infection. However, it was demonstrated that the insect produces three classes of anti-malarial peptides: cecropins, defensins, and gambicins. Recent reports showed that the three classes of peptides present activity against mosquito-stage and, in some cases, blood stage parasites ([@B6]). Thus, cecropins A and B demonstrated activity against ookinetes and oocysts of *P. falciparum, P. berghei, P. knowlesia*, and *P. cymonolgi* ([@B40]; [@B52]), while gambicin displayed 54--64% lethality against *P. berghei* ookinetes at 10--100 μM ([@B101]).

The first report of APPs was described in [@B12]. In this study, they analyzed the growth inhibition of *P. falciparum* cells using different concentrations of cecropin and melittin peptides, called CA (l--13) and H (l--13; [@B12]). During the same year, [@B40] demonstrated the anti-malarial activity of Cecropin B (from giant silk moths) at a concentration of 0.5 μg/μl (128 μM). The peptide prevented normal development of oocysts from *Plasmodium* species in *Anopheles gambiae* insects previously infected with the parasite ([@B40]).

Other important source of anti-malarial peptides was isolated from scorpion and spiders' venoms. Among these peptides, there is scorpine, isolated from the scorpion *Pandinus imperator*, whose structure resembles a hybrid between a defensin and a cecropin. This peptide was responsible for the mortality of 98% of *P. berghei* gametocytes at 15 μM and 100% reduction of *P. falciparum* parasitemia at 5 μM ([@B16]).

Meucine-24, a α-helical peptide with an N-terminal homologous to melittin and meucine-25 have been isolated from the venom of the scorpion *Mesobuthus eupeus* and showed ability to inhibit the development of *P. berghei* ookinetes at micromolar concentrations (IC~50~ 10--20 μM; [@B38]).

Moreover, several insect defensins have displayed anti-malarial activity. Among them, there are two drosomycins isolated from the *Drosophila melanogaster* hemolymph. Drosomycin1 is able to inhibit the development of *P. berghei* ookinetes in 76% at 20 μM, while Drosomycin 2 is able to retard the development of the same parasite in 29% at 20 μM. ([@B95]). Similarly, gomesin, an insect defensin isolated from the hemocytes of the spider *Acanthoscurria gomesiana*, inhibited the *in vitro* growth of intra-erythrocytic forms of *P. falciparum*, causing a dramatic reduction of gametocyte exflagelation and oocyst population in both *P. falciparum* and *P. berghei* ([@B71]).

As described here, multiple compounds can be pharmaceutically attractive to treat Malaria, once that current available anti-malarial drugs are inefficient against parasites. Therefore, novel peptides can open new perspectives for the development of new anti-parasitic drugs ([@B61]; [@B98]).

Structure and Mode of Action of Anti-malarial Peptides
------------------------------------------------------

The description of several anti-microbial peptides with activity against pathogenic bacteria, fungi, protozoa and other harmful organisms are well-described in literature. Those peptides are isolated from different sources, varying from human beings, to plants, insects, marine animals, and even microorganisms ([@B78]; [@B57]; [@B98]; [@B45]). However, few of them show anti-parasitic activity, especially related to human neglected diseases ([@B63]; [@B71]; [@B95]; [@B33]; [@B38]; [@B83]; [@B68]). Among these diseases, Malaria has the most number of published articles on the discovery and characterization of anti-plasmodium proteins and peptides. Considering insect peptides with anti-parasitic activity, Malaria continues reaching the first position in tested molecules, although there are still very few studies demonstrating anti-malarial activities of insect peptides for future use as drugs ([@B12]; [@B40]; [@B101]; [@B52]; [@B71]; [@B16]; [@B95]; [@B38]; [@B98]).

Recently, anti-malarial peptides from insect sources were classified into four groups: (i) α-helical peptides deprived of Cys residues; (ii) β-pleated peptides containing disulfide bridges; (iii) peptides rich in Pro, Gly, His, Arg, and Trp residues; and (iv) circular anti-microbial peptides ([@B98]). Out of these groups, only the first one contains peptides from insect sources with anti-parasitic activities against *Plasmodium* species.

Thus, α-helical peptides deprived of Cys residues correspond to linear cationic small peptides with α-helical structure, whose positive charges come from the presence of Lys and Arg residues. Another feature is the existence of at least 50% of their content composed by hydrophobic amino acid residues ([@B79]). Cecropins (from *H. cecropia*) and Melittins (from *A. mellifera* venom) are some examples of α-helical peptides deprived of Cys residues, due to their α-helical domains and content of hydrophobic residues in the amino-terminal site, respectively ([@B81]; [@B92]).

For insect α-helical peptides deprived of Cys residues, the mode of action consists of poration of the lipid membrane through a disordered toroidally shape lining of peptides (**Figure [1](#F1){ref-type="fig"}**; [@B109]; [@B85]). The charged amino acid residues showed to be essential for electrostatic interactions with the lipid membrane, resulting in pore formation ([@B85]).

![**Mechanism of action of anti-malarial peptides. (A)** Ordered toroidal pore formation. **(B)** Disoredered toroidal pore formation (Source: Segunpta et al., 2008 with modifications).](fmicb-07-00091-g001){#F1}

In general, the mechanism of action of anti-malarial peptides from insect sources are still poorly studied. However, the activities of distinct APPs obey many of the rules governing their ability to disrupt bacterial membranes. The interaction with APPs to the pathogen's cell membrane appears to be acutely influenced by the respective charges and amphipathies of the reactants. In fact, a comparison between the peptides' ability to inhibit the growth of malaria parasites and that of bacteria demonstrates a remarkable parallelism in the way that each modification affects both activities ([@B70]).

Transcriptome: Prospection of Novel Molecules for the Control of Parasitic Diseases
===================================================================================

Transcriptome studies are important to understand the physiology and mechanism of action of parasitic molecules and have been one of the alternatives in seeking resolutions to certain diseases, such as Malaria ([@B93]). In this report, transcriptome and proteome of malaria parasite liver stages displayed essential knowledge about how the parasite behaves inside host cells. Moreover, transcriptome studies are also being used to better understand parasite gene profile during infection, as demonstrated by [@B73]. The report showed changes in *Plasmodium falciparum* transcriptome pattern during its initial phase, describing that modifications were observed even during the first half hour after human transmission by the mosquito ([@B73]). Similarly, [@B41] used transcriptome data from birds infected with *P. relictum*, which causes avian Malaria, to identify and characterize the MSP1 gene (SGS1 and GRW4). The analysis of those genes could led to the generation of a new vaccine for the prevention of avian Malaria, also becoming a relevant result for epidemiological studies ([@B41]).

The evaluation of insect transcriptomes, especially the ones that are hosts of human parasites, have been published for some species. Hence, analyses of *Musca domestica* transcriptome revealed new insights and genes involved in the prophenoloxidase system (proPO), a pathway related to melanization in arthropods. The melanin production occurs after infection, promoting protection against invasion of pathogens, such as bacteria ([@B62]). Therefore, the novel information obtained from transcriptome studies allowed a better understanding on the mechanism of action and immune functions of the proPO system in *M. domestica*.

The inefficiency of therapeutic strategies to treat protozoa-related diseases and the frequent incidence of resistance developed by parasites led to the search for molecules that can be used as new pharmaceutical products for the treatment of parasitic diseases. In the last years, transcriptomes have been employed as promissory source for the prospection of active proteins and peptides. The availability of high-throughput transcriptomic technologies has contributed to considerably enhance the knowledge to understand host--parasite interactions and to identify new and effective treatments for parasitic diseases, especially neglected ones ([@B15]; [@B29]). Furthermore, even transcriptome of phytopathogenic insects could be an interesting source for future prospections of proteins and peptides for therapeutic use on the treatment of Chagas disease, Leishmaniasis, and Malaria ([@B34]; [@B35]).

Anti-Parasitic Peptides: Future Reality for Drug Development?
=============================================================

Several researches are published every year on the prospection and discovery of new molecules from different sources with high potential use as drugs against bacterial, fungi, and parasitic infections ([@B57]; [@B14]; [@B45]; [@B91]). Insect peptides with anti-parasitic activity demonstrate to be an interesting tool on the treatment of neglected diseases, such as Malaria, Leishmaniasis, and Chagas disease.

Many reasons explain why neglected diseases are out of reach from eradication. Hygiene issues, social and economic status of the population and endemic areas full of viable parasite vectors are some of them ([@B3]; [@B32]; [@B53]). Nevertheless, drug inefficiency and misuse, and serious side effects are the main causes of why these diseases are still increasing in number and area worldwide.

The mechanism of action of the drugs used nowadays for the treatment of some neglected diseases are yet not well-known, facilitating mutations triggering drug resistance by the parasites. Moreover, the poor efficient response of such drugs, combined with strong side effects, stimulates the development of alternatives for a better treatment of neglected diseases ([@B94]; [@B98]; [@B100]). As it is occurring with anti-bacterial drugs, the misuse of anti-parasitic drugs is also leading to resistance, increasing preoccupation about a growing arrival of new cases and inefficacy on the treatment of recurrent cases ([@B102]; [@B31]; [@B24]; [@B1]; [@B104]).

Nowadays, anti-parasitic drug candidates containing peptides are still very few, with most of them at Clinical Trials stage ([@B36]). Nonetheless, the fact that pharmaceutical companies continue avoiding the application of peptides for the production of drugs goes beyond oral bioavailability and drug resistance issues. Peptide degradation by digestive enzymes and interactions with plasma proteins are some conditions that complicate the utilization of APPs for production of drugs. Furthermore, the cost of scaling-up the production of organic compounds is still high, contributing to expensive drugs into the market ([@B36]; [@B98]).

However, despite all disadvantages, since the 1990s, the scenario of drug production is changing. The advances on biotechnology applied for the development of new processes for the production of proteins and peptides for therapeutic use stimulated the formulation of different drugs with high specificity and activity toward their targets, at lower costs and using faster production methods ([@B61]). Novel improvements on biocompatible carriers to extend peptide biocompatibility also contributed for enhancing target reach of peptide's site of action ([@B26]; [@B67]). Similarly, use of nanotechnology and peptide encapsulation using biodegradable polymers allowed to increase the precision of drug target, as well as enabled long-acting release forms of peptides in the organism ([@B4]; [@B89]). Therefore, by 2012, numerous peptide drugs were already approved in the US, reflecting in a market of 13 billion dollars, represented by 1.5% of total global drugs sales. Other countries also approved and released peptide drugs over the years, especially the Europeans Germany and UK, responsible for 63% of peptide therapeutics in the market, followed by France, Italy, Scandinavia, and Spain ([@B46]; [@B98]).

Hence, although pharma companies' main target were small molecules (below 500 Da), due to their ease of production and availability for oral application, small drug candidates showed low specificity for their targets, enhancing susceptibility to metabolic inactivation, which increase side effects, dose-response, and decrease their bioavailability ([@B28]). Peptides with average size of 5 kDa, however, displayed high specificity toward their targets, decreasing not only the dose of use, but also harmful side effects. For example, peptide drugs, such as NVB302, OP-145, Omiganan and Pexiganan, are now in Clinical Trials (Phases I, II, and III, respectively), as future effective alternatives for the treatment of Malaria ([@B36]). Therefore, peptide drugs for the treatment of neglected diseases is a reality for future years, with high chances of improvement and expanding in terms of variety and application.

Conclusion
==========

As described before in this report, the activity of insect peptides against the parasites *Trypanosoma* sp., *Leishmania* sp., and *Plasmodium* sp. encourages advances in this research investigation, once there is still a great necessity on developing new effective drugs for the treatment of Chagas disease, Leishmaniasis, and Malaria, respectively. Although poorly explored, insect peptides demonstrate high potential for future application in therapeutics of infectious diseases, especially parasitic neglected ones.

Currently, Malaria, together with other infection disease, such as Tuberculosis and AIDS, receives annually significant amounts of international resources for research on the development of new strategies for their treatment and prevention. Therefore, it was recently removed from the "Neglected disease" group. Nevertheless, there is still no treatment 100% efficient for this disease, but only methods to prolong the life and decrease the pain of patients ([@B74]; [@B97]).

Similarly, Chagas disease continues to represent the parasitic illness responsible for the highest number of deaths in Latin America, surpassing Malaria. Considering that 23% of all infected patients with *T. cruzi* are located in Brazil, this country stands out in the number of published articles about the disease, the parasite, its host vector and on the discovery of novel tools to treat Chagas's disease (more than 1400 publications during the last 70 years). Out of 55 research institutes working with Chagas's disease worldwide, six are locate in Brazil. However, yet, there are very few effective and low toxic drugs available for its treatment.

In the absence of appropriate drugs, Leishmaniasis has also represented a health concern, due to its geographic expansion and urbanization trend. Moreover, the control of human *Leishmania* cannot be done without understanding canine Leishmaniasis, as pet dogs hosting parasites can easily transmit the disease to humans ([@B76]).

Advances on molecular biotechnology allow the production of different proteins and peptides in their active form using several heterologous systems. Therefore, scaling up the production of insect peptides for the development of pharmaceutical drugs to be used on the treatment of parasitic diseases has become a routine technique. Similarly, transcriptome analyses can be a relevant tool on the discovery of novel peptides from insect species with activity against parasites. Therefore, it is clear that insect peptides present high potential to become the future drugs for decreasing the number of infectious diseases, such as Malaria, Leishmaniasis, and Chagas disease.

It is not expected that biotechnological peptides will take over chemical molecules on the development of new drugs. However, peptides are already becoming new options for the treatment of several diseases, from oncology to infectious ones, as they can cause synergic effects, enhancing the efficacy of drugs at lower concentration. Therefore, peptide drugs have reached a place of interest by pharmaceutical companies, where despite of their cost of production and biochemical challenges to overcome, peptides demonstrate to be unique in their mechanism of action and therapeutic use.

Peptide drugs for neglected diseases, such as Malaria, Leishmaniasis, and Chagas diseases, are still at early stages compared to other drugs developed for chronic and non-infectious diseases ([@B59]). But even at a slow pace, studies and researches on peptide drugs are demonstrating to be a reality for the treatment of neglected diseases. For the next 10--15 years, new peptide drugs are expected to be at the market for the treatment of Malaria and, hopefully, for other neglected diseases including Chagas and Leishmaniasis.
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